The investigation of clinical and radiological findings of igG4-related autoimmune pancreatitis

This study aims to investigate the clinical and radiological findings of IgG4-related autoimmune pancreatitis diagnosed in our clinic. The data of patient files diagnosed as IgG4-related autoimmune pancreatitis in our hospital between March 2015 and February 2020 were reviewed retrospectively. 17 cases were included in the study. 10 of the cases were male (59 %) and 7 were female (41 %). Their ages ranged between 47 and 72, and the mean age was 61 ± 4.5. Clinical and laboratory findings with radiological imaging findings of the cases were investigated. The most common symptoms seen during admission to the clinic were obstructive jaundice (65 %), weight loss (53 %) and diabetes mellitus (29 %) that occurred recently. In laboratory examination, there was an increase in CEA and CA 19-9 in 9 patients (53 %). Increased IgG4 was measured in 11 patients (65 %). Some of the patients were accompanied by retroperitoneal fibrosis (3 cases), thyroiditis (2 cases), cholangitis (2 cases) and cholecystitis (1 case). In computed tomography (CT) and Magnetic Resonance Imaging (MRI) examination, diffuse increase in the size of the pancreas was observed in 14 cases (82 %). The focal increased size was most frequently observed in the pancreatic head. Recurrence developed in 5 of the patients (29 %) who received steroid treatment. As a Conclusion, autoimmune pancreatitis is a rare form of chronic pancreatitis that occurs with autoimmune mechanisms. It can be confused clinically with pancreatic cancer. Other extrapancreatic pathologies associated with IgG4 may accompany. Although IgG4 is helpful in diagnosis, the positive predictive value is low. The diagnosis of the disease is very important in terms of treatment. Clinical and radiological findings have an important role in the diagnosis of the disease.

PDF

___

1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394-424.
2. Mottet N, Bellmunt J, Bolla M, et al. EAU-ESTRO-ESUR-SIOG guidelines on prostate cancer. EAU, Arnhem, The Netherlands; 2018. https://uroweb.org/ wp-content/uploads/EAU-ESUR-ESTRO-SIOG-Guidelines-on-ProstateCancer-large-text-V2.pdf
3. Tinay İ, Akgül HM, Tanıdır Y. Metabolik Sendrom ve Benign Prostat Hiperplazisi: Güncelleme. Üroonkoloji Bülteni. 2014;13:206-9.
4. Akgül M, Üren N, Yaman A, Baykan Ö, et al. The Relationship Between Vitamine D Gene Polymorphysms and the Diagnosis of Prostate Cancer at Patients with High PSA Value. Bulletin of Urooncology. 2020.
5. Silva RS, Lombardi AP, Souza DS, et al. Activation of estrogen receptor beta (ERβ) regulates the expression of N cadherin, E-cadherin and β-catenin in androgen-independent prostate cancer cells. International Journal of Biochemistry and Cell Biology. 2018;96:40–50.
6. Musalam A, Andarawi M, Osman M, et al. Alterations of COX-2, HER-2/ neu and E-Cadherin protein expression in the prostatic adenocarcinoma: preliminary findings. Am J Transl Res. 2019;11:1653-67.
7. Olson A, Le V, Aldah J, et al. The comprehensive role of E-cadherin in maintaining prostatic epithelial integrity during oncogenic transformation and tumor progression. PLoS Genet. 2019;15:e1008451.
8. Abdallah RA, Abdou AG, Abdelwahed M, et al. Immunohistochemical Expression of E‑ and N‑Cadherin in Nodular Prostatic Hyperplasia and Prostatic Carcinoma. J Microsc Ultrastruct. 2019;7:19-27.
9. Jaggi M, Johansson SL, Baker JJ, et al. Aberrant expression of E-cadherin and beta-catenin in human prostate cancer. Urol. Oncol. Semin. Orig. Investig. 2005;23:402–6
10. Kypta R, Waxman J. Wnt/β-catenin signalling in prostate cancer. Nat Rev Urol. 2012;9,418–28.
11. Jaggi M, Johansson SL, Baker JJ, et al. Aberrant expression of E-cadherin and beta-catenin in human prostate cancer. Urol. Oncol. Semin. Orig. Investig. 2005;23:402–6.
12. Polakis P. Wnt signaling and cancer. Genes Dev. 2000;14:1837–51.
13. Korinek V, Barker N, Morin PJ, et al. Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma. Science. 1997;275:1784–7.
14. Chen G, Shukeir N, Potti A, et al. Up-regulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications. Cancer. 2004;101:1345–56.
15. Lean FZX, Kontos S, Palmieri C. Expression of β-catenin and mesenchymal markers in canine prostatic hyperplasia and carcinoma. J Comp Pathol. 2014;150.373–81.
16. Schmalhofer O, Brabletz S, Brabletz T. E-cadherin, β-catenin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev. 2009;28:151–66.
17. Chunthapong J, Seftor EA, Khalkhali-Ellis Z, et al. Dual roles of E-cadherin in prostate cancer invasion. J Cell Biochem. 2004;91;649-61.
18. Toivanen R, Mohan A, Shen MM. Basal Progenitors Contribute to Repair of the Prostate Epithelium Following Induced Luminal Anoikis. Stem Cell Reports. 2016;6:660–7.
19. Gayther SA, Gorringe KL, Ramus SJ, et al. Identification of germ-line E-cadherin mutations in gastric cancer families of European origin. Cancer Res. 1998;58:4086–9.
20. Guilford P, Hopkins J, Harraway J, et al. E-cadherin germline mutations in familial gastric cancer. Nature. 1998;392:402–5.
21. Arenas MI, Romo E, Royuela M, et al. N and P cadherin, and alpha, beta and gammacatenin protein expression in normal, hyperplastic and carcinomatous human prostate. Histochem J. 2000;32(:659-67.
22. Kobayashi PE, Fonseca-Alves CE, Rivera-Calderón LG, et al. Deregulation of E-cadherin, β-catenin, APC and Caveolin-1 expression occurs in canine prostate cancer and metastatic processes. Res Vet Sci. 2018;118:254-61.
23. Koksal IT, Ozcan F, Kilicaslan I, et al. Expression of E-Cadherin in prostate cancer in formalin-fixed, paraffin-embedded tissues: correlation with pathological features. Pathology. 2002;34:233-8.
24. Akgül M, Garayev A, Tinay İ. Active surveillance in prostate cancer: can we expand the indications? Bulletin of Urooncology. 2016;15:163-6.